Antagonist of secondary lymphoid-tissue chemokine (CCR ligand 21) prevents the development of chronic graft-versus-host disease in mice

Journal of Immunology

Volumn 170, Issue 1, 2003, Pages 588-596

  Sasaki, Miho ^a   Hasegawa, Hitoshi ^a   Kohno, Masashi ^a   Inoue, Atsushi ^a   Ito, Mitsuko R ^a   Fujita, Shigeru ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CALCIUM ION; CD4 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR7; CONCANAVALIN A; DNA ANTIBODY; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1; INTERLEUKIN 2; INTERLEUKIN 4; IODINE 125; MONOCLONAL ANTIBODY; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHEMOTAXIS; CHRONIC DISEASE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GENE EXPRESSION; GRAFT VERSUS HOST REACTION; IMMUNOHISTOCHEMISTRY; LYMPHOID TISSUE; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECEPTOR BINDING; SPLEEN CELL; T LYMPHOCYTE;

EID: 0037223254     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.1.588     Document Type: Article

References (60)

1. Ho, V. T., and R. J. Soiffer. 2001. The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98:3192.
2. Vogelsang, G. B. 2001. How I treat chronic graft-versus-host disease. Blood 97:1196.
3. Schmitz, N., A. Bacigalupo, D. Hasenclever, A. Nagler, E. Gluckman, P. Clark, P. Bourquelot, H. Greinix, N. Frickhofen, O. Ringden, et al. 1998. Allogeneic bone marrow transplantation vs. filgrastim-mobilised peripheral blood progenitor cell transplantation in patients with early leukemia: First results of a randomized multicentre trial of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant. 21:995.
4. Vigorito, A. C., W. N. Azevedo, J. F. Marques, A. M. Azevedo, K. A. Eid, F. J. Aranha, I. Lorand-Metze, G. B. Oliveira, M. E. Correa, A. R. Reis, et al. 1998. A randomized, prospective comparison of allogeneic bone marrow and peripheral blood progenitor cell transplantation in the treatment of haematological malignancies. Bone Marrow Transplant. 22:1145.
5. Powles, R., J. Mehta, S. Kulkarni, J. Treleaven, B. Millar, J. Marsden, V. Shepherd, A. Rowland, B. Sirohi, D. Tait, et al. 2000. Allogeneic blood and bone-marrow stem-cell transplantation in haematological malignant diseases: A randomized trial. Lancet 335:1231.
6. Bensinger, W. I., P. J. Martin, B. Storer, R. Clift, S. J. Forman, R. Negrin, A. Kashyap, M. E. Flowers, K. Lilleby, T. R. Chauncey, et al. 2001. Transplantation of bone marrow as compared with peripheral-blood cells from HLA-identical relatives in patients with hematologic cancers. N. Engl. J. Med. 344:175.
7. Cutler. C., S. Giri, S. Jeyapalan, D. Paniagua, A. Viswanathan, and J. H. Antin, 2001. Acute and chronic graft-versus-host disease after allogeneic peripheralblood stem-cell and bone marrow transplantation: A meta-analysis. J. Clin. Oncol. 19:3685.
8. Ferrara, J. L., and W. Krenger. 1998. Graft-versus-host disease: The influence of type 1 and type 2 T cell cytokines. Transfus. Med. Rev. 12:1.
9. Krenger, W., and J. L. Ferrara. 1996. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol. Res. 15:50.
10. Gleichmann, E., S. T. Pals, A. G. Rolonk, T. Padoszkiewicz, and H. Glechmann. 1984. Graft-versus-host reactions: Clues to the etiopathology of a spectrum of immunological diseases. Immunol. Today 5:324.
11. Doutrelepont, J. M., M. Moser, O. Leo, D. Abramowiz, M. L. Vanderhaegen, J. Urbain, and M. Goldman. 1991. Hyper IgE in stimulatory graft-versus-host disease: Role of interleukin-4. Clin. Exp. Immunol. 83:133.
12. + T cells. J. Intmunol. 155:2396.
13. Via, C. S., and G. M. Shearer. 1988. T-cell interactions in autoimmunity: Insights from a murine model of graft-versus-host disease. Immunol. Today 9:207.
14. Zlotonik, A., and O. Yoshie. 2000. Chemokines: A new classification system and their role in immunity. Immunity 12:121.
15. Hasegawa, H., and S. Fujita. 2001. Chemokines and lymphocytes: The role of chemokines and their receptors in the immune system. Cell. Mol. Biol. 47:599.
16. Nagira, M., T. Imai, K. Hieshima, J. Kusuda, M. Ridanpaa, S. Takagi, M. Nishimura, M. Kakizaki, H. Nomiyama, and O. Yoshie. 1997. Molecular cloning of a novel human CC chemokine secondary lymphoid-tissue chemokine that is a potent chemoattractant for lymphocytes and mapped to chromosome 9p13. J. Biol. Chem. 272:19518.
17. Yoshida, R., T. Imai, K. Hieshima, J. Kusuda, M. Baba, M. Kitaura, M. Nishimura, M. Kakizaki, H. Nomiyama, and O. Yoshie. 1997. Molecular cloning of a novel human CC chemokine EB11-ligand chemokine that is a specific functional ligand for EB11/CCR7. J. Biol. Chem. 272:13803.
18. Gunn, M. D., K. Tangemann, C. Tam, J. G. Cyster, S. D. Rosen, and L. T. Williams. 1998. A chemokine expressed in lymphoid high endothelial venules promotes the adhesion and chemotaxis of naïve T lymphocytes. Proc. Natl. Acad. Sci. USA 95:258.
19. Ngo, V. N., H. L. Tang, and J. G. Cyster. 1998. Epstein-Barr virus-induced molecule 1 ligand chemokine is expressed by dendritic cells in lymphoid tissues and strongly attracts naive T cells and activated B cells. J. Exp. Med. 188:181.
20. Warnock, R. A., J. J. Campbell, M. E. Dorf, A. Matsuzawa, L. M. McEvoys, and E. C. Butcher. 2000. The role of chemokines in the microenvironmental control of T versus B cell arrest in Peyer's patch high endothelial venules. J. Exp. Med. 191:77.
21. Iwasaki, A., and B. L. Kelsall. 2000. Localization of distinct Peyer's patch dendritic cell subsets and their recruitment by chemokines macrophage inflammatory protein (MIP)-3α, MIP-3β, and secondary lymphoid organ chemokine. J. Exp. Med. 191:1381.
22. Baekkevold, E. S., T. Yamanaka, R. T. Palframan, H. S. Carlsen, F. P. Reinholt, U. H. von Andrian, P. Brandtzaeg, and G. Haraldsen. 2001. The CCR7 ligand ELC (CCL19) is transcytosed in high endothelial venules and mediates T cell recruitment. J. Exp. Med. 193:1105.
23. Birkenbach, M., K. Josefsen, R. Yalamanchili, G. Lenoir, and E. Kieff. 1993. Epstein-Barr virus-induced genes, first lymphocyte-specific G protein-coupled peptide receptors. J. Virol. 67:2209.
24. + T cells. J. Virol. 68:5326.
25. Hasegawa, H., T. Nomura, M. Kohno, N. Tateishi, Y. Suzuki, N. Maeda, R. Fujisawa, O. Yoshie, and S. Fujita. 2000. Increased chemokine receptor CCR7/EB11 expression enhances the infiltration of lymphoid organs by adult T-cell leukemia cells. Blood 95:30.
26. Gunn, M. D., S. Kyuwa, C. Tam, T. Kakiuchi, A. Matsuzawa, L. T. Williams, and H. Nakano. 1999. Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization, J. Exp. Med. 189:451.
27. Forster, R., A. Schubel, D. Breitfeld, E. Kremmer, I. Renner-Muller, E. Wolf, and M. Lipp. 1999. CCR7 coordinates the primary immune response by establishing functional microenvironments in secondary lymphoid organs. Cell 99:23.
28. 2-terminal residues. J. Exp. Med. 181:631.
29. 2-terminal residue converts monocyte chemotactic protein 1 from an activator of basophil mediator release to an eosinophil cheoattractant. J. Exp. Med. 183:681.
30. Proudfoot, A. E., C. A. Power, A. J. Hoogewerf, M. O. Motjovent, F. Borlat, R. E. Offord, and T. N. Wells. 1996. Extension of recombinant human RANTES by the retention of the initiating methionine produces a potent antagonist. J. Biol. Chem. 271:2599.
31. Proost, P., S. Struyf, M. Couvreur, J. P. Lenaerts, R. Conings, P. Menten, P. Verhaert, A. Wuyts, and J. Van Damme. 1998. Posttranslational modifications affect the activity of the human monocyte chemotactic proteins MCP-1 and MCP-2: identification of MCP-2 (6-76) as a natural chemokine inhibitor. J. Immunol. 160:4034.
32. Simmons, G., P. R. Clapham, L. Picard, R. E. Offord, M. M. Rosenkidle, T. W. Schwartz, R. Buser, T. N. Wells, and A. E. Proudfoot. 1997. Potent inhibition of HIV-1 infectivity in macrophages and lymphocytes by a novel CCR5 antagonist. Science 276:276.
33. Gong, J. H., M. Uguccioni, B. Dewald, M. Baggiolini, and I. Clark-Lewis. 1996. RANTES and MCP-3 antagonists bind multiple chemokine receptors. J. Biol. Chem. 271:10521.
34. Struyf, S., I. De Meester, S. Scharpe, J. P. Lenaerts, P. Menten, J. M. Wang, P. Proost, and J. Van Damme. 1998. Natural truncation of RANTES abolishes signaling through the CC chemokine receptors CCR1 and CCR3, impairs its chemotactic potency and generates a CC chemokine inhibitor. Eur. J. Immunol. 28:1262.
35. Hebert, C. A., R. V. Vitangcol, and J. B. Baker. 1991. Scanning mutagenesis of interleukin-8 identifies a cluster of residues required for receptor binding. J. Biol. Chem. 266:18989.
36. Moser, B., B. Dewald, L. Barella, C. Schumacher, M. Baggiolini, and I. Clark-Lewis. 1993. Interluekin-8 antagonists generated by N-terminal modification. J. Biol. Chem. 268:7125.
37. Hedrick, J. A., and A. Zlotnik. 1997. Identification and characterization of a novel β chemokine containing six conserved cysteines. J. Immunol. 159:1589.
38. Hasegawa, H., Y. Utsunomiya, K. Kishimoto, K. Yanagisawa, and S. Fujita. 1996. SFA-1, a novel cellular gene induced by human T-cell leukemia virus type 1, is a member of the transmembrane 4 superfamily. J. Virol. 70:3258.
39. Hasegawa, H., H. Watanabe, T. Nomura, Y. Utsunomiya, K. Yanagisawa, and S. Fujita. 1997. Molecular cloning and expression of mouse homologue of SFA-1/PETA-3 (CD151), a member of the transmembrane 4 superfamily. Biochim. Biophys. Acta 1353:125.
40. Nomura, T., H. Hasegawa, M. Kohno, M. Sasaki, and S. Fujita. 2001. Enhancement of anti-tumor immunity by tumor cells transfected with the secondary lymphoid tissue chemokine EB1-1-ligand chemokine and stromal cell-derived factor-1 α chemokine genes. Int. J. Cancer 91:597.
41. 1 integrin and regulates adhesion of human T cell leukemia virus typel-infected T cells to fibronectin. J. Immunol. 167:3087.
42. Fernandez, E. J., and E. Lolis. 2002. Structure, function, and inhibition of chemokines. Annu. Rev. Pharmacol. Toxicol. 42:469.
43. Baldwin, E. T., I. T. Weber, R. St. Charles, J. C. Xuan, E. Appella, M. Yamada, K. Matsushima, B. F. Edwards, G. M. Clore, A. M. Gronenborn. and A. Wlodawer. 1991. Crystal structure of interleukin 8: Symbiosis of NMR and crystallography. Proc. Natl. Acad. Sci. USA 88:502.
44. Clore, M. G., E. Appella, M. Yamada, K. Matsushima, and A. Gronenborn. 1990. Three dimensional structure of interleukin 8 in solution. Biochemistry 24:1689.
45. Lubkowski, J., G. Bujacz, L. Boque, P. Domaille, T. Handel, and A. Wlondawer. 1997. The structure of MCP-1 in two crystal forms provides a rare example of variable quaternary interactions. Nat. Struct. Biol. 4:64.
46. Handel, T. M., and P. J. Domaille. 1996. Heteronuclear (1H, 13C, 15N) NMR assignments and solution structure of the monocyte chemoattractant protein-1 (MCP-1) dimer. Biochemistry 35:6569.
47. Blaszczyk, J., E. V. Coillie, P. Proost, J. V. Damme, G. Opdenakker, G. D. Bujacz, J. M. Wang, and X. Ji. 2000. Complete crystal structure of monocyte chemotactic protein-2, a CC chemokine that interacts with multiple receptors. Biochemistry 39:14075.
48. Kim, K. M., K. Rajarathnam, I. Clark-Lewis, and B. D. Sykes. 1996. Structural characterization of monomeric chemokine: Monocyte chemoattractant protein-3. FEBS Lett. 395:277.
49. Mayer, M. R., and M. J. Stone. 2001. Identification of receptor binding and activation determinants in the N-terminal and N-loop regions of the CC chemokine Eotaxin. J. Biol. Chem. 276:13911.
50. Chung, C., R. Cooke, A. Proudfoot, and T. Wells. 1995. The three-dimensional solution structure of RANTES. Biochemistry 34:9307.
51. Czaplewski, L. G., J. McKeating, C. J. Craven, L. D. Higgins, V. Appay, A. Brown, T. Dudgeon, L. A. Howard, T. Meyers, J. Owen, et al. 1999. Identification of amino acid residues critical for aggregation of human CC chemokines macrophage inflammatory protein (MIP)-1 α, MIP-1 β, and RANTES: Characterization of active disaggregated chemokine variants. J. Biol. Chem. 274:16077.
52. Lodi, P. J., D. S. Garrett, J. Kuszewski, M. L. Tsang, J. A. Weatherbee, W. J. Leonard, A. M. Gronenbom, and G. M. Clore. 1994. High-resolution solution structure of the β chemokine hMIP-1β by multidimensional NMR. Science 265:1762.
53. Hoover, D. M., L. S. Mizoue, T. M. Handle, and J. Lubkowski. 2000. The crystal structure of the chemokine domain of fractalkine shows novel quaternary arrangement. J. Biol. Chem. 275:23187.
54. Mizoue, L. S., J. F. Bazan, E. C. Johnson, and T. M. Handle. 1999. Solution structure and dynamics of the CX3C chemokine domain of fractalkine and its interaction with an N-terminal fragment of CX3CR1. Biochemistry 38:1402.
55. Dealwis, C., E. J. Fernandez, D. A. Thompson, R. J. Simon, M. A. Siani, and E. Lolis. 1998. Crystal structure of chemically synthesized (N33A) stromal cell-derived factor 1α, a potent ligand for the HIV-1 "fusion" coreceptor. Proc. Natl. Acad. Sci. USA 95:6941.
56. Crump, M. P., J. H. Gong, P. Loetscher, K. Rajarathnam, A. Amara, F. Arenzana-Seisdedos, J. L. Virelizier, M. Baggioloni, B. D. Sykes, and I. Clark-Lewis. 1997. Solution structure and basis for functional activity of stromal cell-derived factor-1; dissociation of CXCR4 activation from binding and inhibition of HIV-1. EMBO J. 16:6996.
57. Butcher, E. C., and L. J. Picher. 1996. Lymphocyte homing and homeostasis. Science 272:60.
58. + T lymphocytes in the pathogenesis of liver injury in graft-versus-host disease. J. Clin. Invest. 104:49.
59. + T cells to the liver, lung, and spleen during graft-versus-host disease. Blood 96:2973.
60. Zhang, Y., L. L. McCormick, S. R. Desai, C. Wu, and A. C. Gilliam. 2002. Murine sclerodermatous graft-versus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J. Immunol. 168:3088.